» Articles » PMID: 31602271

Differential Impact of Classical and Non-canonical NF-κB Pathway-related Gene Expression on the Survival of Breast Cancer Patients

Overview
Journal J Cancer
Specialty Oncology
Date 2019 Oct 12
PMID 31602271
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation is a well-known driver of carcinogenesis and cancer progression, often attributed to the tumor microenvironment. However, tumor cells themselves are capable of secreting a variety of inflammatory molecules, leading to the activation of specific signaling pathways that promote tumor progression. The NF-κB signaling pathway is one of the most important connections between inflammation and tumorigenesis. NF-κB is a superfamily of transcription factors that plays an important role in several types of hematological and solid tumors, including breast cancer. However, the role of the NF-κB pathway in the survival of breast cancer patients is poorly studied. In this study, we analyzed and related the expression of both canonical and alternative NF-κB pathways and selected target genes with the relapse-free and overall survival of breast cancer patients. We used the public database Kaplan-Meier plotter (KMplot) which includes gene expression data and survival information of 3951 breast cancer patients. We found that the expression of was associated with poor relapse-free survival in patients with ER-positive tumors. Moreover, the expression of and was associated with poor relapse-free and overall survival. In contrast, expression of , and from the canonical pathway, and and from the alternative pathway correlated with better relapse-free survival also when the patients were classified by their hormonal and nodal status. Our study suggests that the expression of genes of the canonical and alternative NF-κB pathways is ultimately critical for tumor persistence. Understanding the communication between both pathways would help to find better therapeutic and prophylactic targets to prevent breast cancer progression and relapse.

Citing Articles

A novel PD-1/PD-L1 pathway-related seven-gene signature for the development and validation of the prognosis prediction model for breast cancer.

Zhang P, Yang J, Zhong X, Selistre-de-Araujo H, Boussios S, Ma Y Transl Cancer Res. 2024; 13(3):1554-1566.

PMID: 38617520 PMC: 11009795. DOI: 10.21037/tcr-23-2270.


Transcriptional Regulation during Aberrant Activation of NF-κB Signalling in Cancer.

Deka K, Li Y Cells. 2023; 12(5).

PMID: 36899924 PMC: 10001244. DOI: 10.3390/cells12050788.


Paclitaxel resistance is mediated by NF-κB on mesenchymal primary breast cancer cells.

Esparza-Lopez J, Longoria O, De La Cruz-Escobar E, Garibay-Diaz J, Leon-Rodriguez E, Ibarra-Sanchez M Oncol Lett. 2022; 23(2):50.

PMID: 34992683 PMC: 8721864. DOI: 10.3892/ol.2021.13168.


Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients.

Grillo P, Gyorffy B, Gotte M J Cancer Res Clin Oncol. 2021; 147(7):1937-1955.

PMID: 33742285 PMC: 8164625. DOI: 10.1007/s00432-021-03597-4.


c-Myb interferes with inflammatory IL1α-NF-κB pathway in breast cancer cells.

Ducka M, Kucerikova M, Trcka F, Cervinka J, Biglieri E, Smarda J Neoplasia. 2021; 23(3):326-336.

PMID: 33621853 PMC: 7905261. DOI: 10.1016/j.neo.2021.01.002.


References
1.
Becker S . A historic and scientific review of breast cancer: The next global healthcare challenge. Int J Gynaecol Obstet. 2015; 131 Suppl 1:S36-9. DOI: 10.1016/j.ijgo.2015.03.015. View

2.
Benoy I, Salgado R, van Dam P, Geboers K, Van Marck E, Scharpe S . Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004; 10(21):7157-62. DOI: 10.1158/1078-0432.CCR-04-0812. View

3.
Kreso A, Dick J . Evolution of the cancer stem cell model. Cell Stem Cell. 2014; 14(3):275-91. DOI: 10.1016/j.stem.2014.02.006. View

4.
Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y . Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 2009; 100(9):1668-74. PMC: 11158550. DOI: 10.1111/j.1349-7006.2009.01228.x. View

5.
McGowan P, Duffy M . Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 2008; 19(9):1566-72. DOI: 10.1093/annonc/mdn180. View